Multiple Myeloma Treatment 2026: CAR-T vs Bispecific Antibodies (Evidence-Based Guide)
Introduction: A Turning Point in Multiple Myeloma (2026) The treatment landscape for multiple myeloma has undergone a dramatic transformation between 2021 and 2026. What was once a disease dominated by sequential chemotherapy and monoclonal antibodies is now entering the era of cellular therapy and T-cell–redirecting immunotherapy . Two modalities are now reshaping outcomes: CAR-T cell therapy (chimeric antigen receptor T cells) Bispecific antibodies (T-cell engagers) Both target key antigens such as BCMA (B-cell maturation antigen) and GPRC5D , enabling the immune system to directly eliminate malignant plasma cells. But a critical question remains: 👉 Which is better—CAR-T or bispecific antibodies? And when should each be used? This guide synthesizes the latest 2026 clinical data, dosing protocols, and real-world insights into a practical, SEO-optimized resource. The Evolution of Myeloma Treatment (2021–2026) From Late-Line Rescue to Early-Line Strategy Between 2021 and 2022: CAR-T t...